 Laura Borgelt
Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitamins | 3 | 2025 | 182 | 1.880 |
Why?
| | Contraceptive Agents | 3 | 2022 | 66 | 1.420 |
Why?
| | Medical Marijuana | 6 | 2020 | 122 | 1.380 |
Why?
| | Dietary Supplements | 3 | 2025 | 583 | 1.230 |
Why?
| | Cannabis | 6 | 2021 | 509 | 1.180 |
Why?
| | Education, Pharmacy | 7 | 2022 | 120 | 1.170 |
Why?
| | Minerals | 3 | 2025 | 48 | 1.160 |
Why?
| | Marijuana Use | 3 | 2018 | 222 | 0.930 |
Why?
| | Contraception, Postcoital | 2 | 2023 | 9 | 0.930 |
Why?
| | Metals, Heavy | 1 | 2025 | 31 | 0.870 |
Why?
| | Faculty, Pharmacy | 2 | 2022 | 20 | 0.860 |
Why?
| | Contraindications, Drug | 1 | 2024 | 10 | 0.850 |
Why?
| | Dronabinol | 5 | 2022 | 249 | 0.820 |
Why?
| | Contraceptives, Oral, Hormonal | 2 | 2015 | 30 | 0.810 |
Why?
| | Polypharmacy | 1 | 2024 | 94 | 0.780 |
Why?
| | Schools, Pharmacy | 2 | 2020 | 48 | 0.730 |
Why?
| | Levonorgestrel | 3 | 2023 | 34 | 0.720 |
Why?
| | Abortion, Induced | 1 | 2023 | 110 | 0.690 |
Why?
| | Perimenopause | 1 | 2022 | 69 | 0.670 |
Why?
| | Pregnancy | 13 | 2025 | 7202 | 0.660 |
Why?
| | Nonprescription Drugs | 2 | 2018 | 69 | 0.640 |
Why?
| | Antirheumatic Agents | 1 | 2021 | 307 | 0.540 |
Why?
| | Epilepsy | 3 | 2020 | 390 | 0.540 |
Why?
| | Endocannabinoids | 1 | 2018 | 56 | 0.540 |
Why?
| | Breast Feeding | 2 | 2018 | 446 | 0.530 |
Why?
| | Anticonvulsants | 2 | 2020 | 246 | 0.520 |
Why?
| | Prescription Drugs | 1 | 2018 | 111 | 0.480 |
Why?
| | Contraceptive Agents, Female | 2 | 2014 | 80 | 0.470 |
Why?
| | Teratogens | 1 | 2015 | 25 | 0.460 |
Why?
| | Mental Disorders | 1 | 2024 | 1163 | 0.440 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 503 | 0.420 |
Why?
| | Intrauterine Device Migration | 1 | 2013 | 3 | 0.410 |
Why?
| | Migraine Disorders | 1 | 2016 | 114 | 0.410 |
Why?
| | Uterine Perforation | 1 | 2013 | 4 | 0.410 |
Why?
| | Curriculum | 3 | 2020 | 1070 | 0.400 |
Why?
| | Pharmacists | 5 | 2021 | 258 | 0.400 |
Why?
| | Intrauterine Devices, Medicated | 1 | 2013 | 27 | 0.390 |
Why?
| | Students, Pharmacy | 3 | 2021 | 96 | 0.370 |
Why?
| | Phytotherapy | 1 | 2013 | 74 | 0.370 |
Why?
| | Drug Labeling | 1 | 2012 | 37 | 0.360 |
Why?
| | Drug and Narcotic Control | 1 | 2012 | 24 | 0.360 |
Why?
| | Nandrolone | 1 | 2011 | 3 | 0.360 |
Why?
| | Vomiting | 3 | 2017 | 131 | 0.360 |
Why?
| | Arthritis, Rheumatoid | 1 | 2021 | 1180 | 0.350 |
Why?
| | Contraceptives, Oral, Combined | 1 | 2011 | 18 | 0.350 |
Why?
| | Contraception | 4 | 2022 | 170 | 0.350 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2018 | 652 | 0.340 |
Why?
| | Humans | 36 | 2025 | 145474 | 0.320 |
Why?
| | Female | 23 | 2025 | 78844 | 0.320 |
Why?
| | Postpartum Period | 1 | 2013 | 373 | 0.320 |
Why?
| | Community Pharmacy Services | 2 | 2021 | 46 | 0.290 |
Why?
| | Hallucinogens | 2 | 2022 | 111 | 0.290 |
Why?
| | Estradiol | 1 | 2011 | 515 | 0.270 |
Why?
| | Young Adult | 8 | 2024 | 14218 | 0.260 |
Why?
| | Cannabidiol | 2 | 2020 | 142 | 0.250 |
Why?
| | Cannabinoids | 3 | 2018 | 184 | 0.250 |
Why?
| | Adolescent | 8 | 2024 | 22529 | 0.250 |
Why?
| | Educational Measurement | 3 | 2017 | 326 | 0.230 |
Why?
| | Iodine | 1 | 2025 | 27 | 0.220 |
Why?
| | Menopause | 2 | 2022 | 326 | 0.220 |
Why?
| | Prevalence | 2 | 2024 | 2865 | 0.210 |
Why?
| | New York | 1 | 2024 | 128 | 0.210 |
Why?
| | Alabama | 1 | 2023 | 32 | 0.200 |
Why?
| | Choline | 1 | 2025 | 137 | 0.200 |
Why?
| | Contraceptives, Oral | 1 | 2023 | 37 | 0.200 |
Why?
| | Psychotropic Drugs | 1 | 2024 | 78 | 0.200 |
Why?
| | Marijuana Abuse | 4 | 2018 | 213 | 0.190 |
Why?
| | Antipsychotic Agents | 1 | 2024 | 211 | 0.180 |
Why?
| | Diet | 2 | 2021 | 1277 | 0.170 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5904 | 0.170 |
Why?
| | Faculty | 1 | 2022 | 147 | 0.160 |
Why?
| | Prescriptions | 1 | 2021 | 74 | 0.160 |
Why?
| | Medicaid | 1 | 2024 | 467 | 0.150 |
Why?
| | Adult | 10 | 2021 | 40777 | 0.150 |
Why?
| | Methotrexate | 1 | 2021 | 233 | 0.150 |
Why?
| | Progesterone | 1 | 2021 | 215 | 0.150 |
Why?
| | United States | 5 | 2024 | 16098 | 0.150 |
Why?
| | Professional Competence | 1 | 2019 | 91 | 0.140 |
Why?
| | Lennox Gastaut Syndrome | 1 | 2019 | 19 | 0.140 |
Why?
| | Directive Counseling | 1 | 2018 | 45 | 0.140 |
Why?
| | Plant Extracts | 1 | 2020 | 188 | 0.140 |
Why?
| | Retrospective Studies | 6 | 2021 | 17291 | 0.140 |
Why?
| | Length of Stay | 2 | 2021 | 1349 | 0.140 |
Why?
| | Health Care Costs | 1 | 2021 | 425 | 0.140 |
Why?
| | Stillbirth | 1 | 2018 | 81 | 0.130 |
Why?
| | Off-Label Use | 1 | 2018 | 51 | 0.130 |
Why?
| | Fertilization | 1 | 2018 | 43 | 0.130 |
Why?
| | Infant, Low Birth Weight | 1 | 2018 | 156 | 0.130 |
Why?
| | Congenital Abnormalities | 1 | 2018 | 109 | 0.130 |
Why?
| | Child | 6 | 2024 | 22707 | 0.130 |
Why?
| | Colorado | 5 | 2018 | 4553 | 0.130 |
Why?
| | Commerce | 1 | 2018 | 80 | 0.130 |
Why?
| | Micronutrients | 1 | 2018 | 102 | 0.130 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2017 | 13 | 0.130 |
Why?
| | Drug Therapy | 1 | 2017 | 84 | 0.130 |
Why?
| | Problem-Based Learning | 2 | 2017 | 97 | 0.130 |
Why?
| | Professional-Patient Relations | 1 | 2018 | 147 | 0.120 |
Why?
| | Pharmacies | 1 | 2017 | 40 | 0.120 |
Why?
| | Infant, Newborn | 2 | 2018 | 6447 | 0.120 |
Why?
| | United States Food and Drug Administration | 2 | 2017 | 208 | 0.110 |
Why?
| | Prenatal Care | 1 | 2018 | 309 | 0.110 |
Why?
| | Risk Factors | 2 | 2022 | 10885 | 0.110 |
Why?
| | Fetal Development | 1 | 2018 | 298 | 0.110 |
Why?
| | Women | 1 | 2015 | 47 | 0.110 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 291 | 0.110 |
Why?
| | Leadership | 1 | 2019 | 401 | 0.110 |
Why?
| | Premature Birth | 1 | 2018 | 388 | 0.100 |
Why?
| | Faculty, Medical | 1 | 2017 | 303 | 0.100 |
Why?
| | Drug Interactions | 1 | 2015 | 405 | 0.100 |
Why?
| | Administration, Oral | 2 | 2019 | 866 | 0.100 |
Why?
| | Pharmaceutical Services | 1 | 2014 | 76 | 0.100 |
Why?
| | Child, Preschool | 3 | 2024 | 11853 | 0.100 |
Why?
| | Spasm | 1 | 2013 | 21 | 0.100 |
Why?
| | Self Report | 1 | 2017 | 870 | 0.100 |
Why?
| | Receptor, Cannabinoid, CB1 | 1 | 2013 | 39 | 0.090 |
Why?
| | Estrogen Replacement Therapy | 1 | 2014 | 143 | 0.090 |
Why?
| | Parents | 1 | 2021 | 1403 | 0.090 |
Why?
| | Program Evaluation | 1 | 2017 | 943 | 0.090 |
Why?
| | Counseling | 1 | 2015 | 400 | 0.090 |
Why?
| | Infant | 2 | 2024 | 10077 | 0.090 |
Why?
| | Drug Approval | 1 | 2012 | 93 | 0.090 |
Why?
| | Teaching | 1 | 2014 | 237 | 0.090 |
Why?
| | Animals | 5 | 2022 | 38030 | 0.090 |
Why?
| | Macaca mulatta | 2 | 2022 | 186 | 0.080 |
Why?
| | Radiography | 1 | 2013 | 852 | 0.080 |
Why?
| | Risk | 1 | 2013 | 919 | 0.080 |
Why?
| | Interpersonal Relations | 1 | 2014 | 397 | 0.080 |
Why?
| | Drug Costs | 1 | 2011 | 117 | 0.080 |
Why?
| | Drug Combinations | 1 | 2011 | 396 | 0.080 |
Why?
| | Surveys and Questionnaires | 2 | 2020 | 6066 | 0.080 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 261 | 0.080 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 782 | 0.080 |
Why?
| | Male | 6 | 2024 | 72842 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2013 | 1061 | 0.070 |
Why?
| | Nausea | 2 | 2018 | 112 | 0.060 |
Why?
| | Pain | 1 | 2013 | 789 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2013 | 11772 | 0.060 |
Why?
| | Health Services Accessibility | 3 | 2020 | 1101 | 0.060 |
Why?
| | Aged, 80 and over | 1 | 2016 | 8333 | 0.050 |
Why?
| | Cannabinoid Receptor Agonists | 1 | 2022 | 44 | 0.050 |
Why?
| | Periodicity | 1 | 2021 | 58 | 0.040 |
Why?
| | Prolactin | 1 | 2021 | 87 | 0.040 |
Why?
| | Anti-Mullerian Hormone | 1 | 2021 | 61 | 0.040 |
Why?
| | Thyrotropin | 1 | 2021 | 120 | 0.040 |
Why?
| | Luteinizing Hormone | 1 | 2021 | 207 | 0.040 |
Why?
| | Reproductive Health | 1 | 2021 | 91 | 0.040 |
Why?
| | Menstrual Cycle | 1 | 2021 | 145 | 0.040 |
Why?
| | Follicle Stimulating Hormone | 1 | 2021 | 266 | 0.040 |
Why?
| | Trust | 1 | 2021 | 155 | 0.040 |
Why?
| | Middle Aged | 3 | 2017 | 36215 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2019 | 115 | 0.040 |
Why?
| | Half-Life | 1 | 2019 | 155 | 0.040 |
Why?
| | Biological Availability | 1 | 2019 | 145 | 0.040 |
Why?
| | Staff Development | 1 | 2019 | 63 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2019 | 335 | 0.030 |
Why?
| | Morning Sickness | 1 | 2018 | 3 | 0.030 |
Why?
| | Fetus | 1 | 2022 | 804 | 0.030 |
Why?
| | Pregnancy Trimester, First | 1 | 2018 | 139 | 0.030 |
Why?
| | Delphi Technique | 1 | 2019 | 332 | 0.030 |
Why?
| | Legislation, Drug | 1 | 2018 | 73 | 0.030 |
Why?
| | Professional Role | 1 | 2018 | 169 | 0.030 |
Why?
| | Placenta | 1 | 2022 | 786 | 0.030 |
Why?
| | Syndrome | 1 | 2016 | 381 | 0.030 |
Why?
| | Aged | 1 | 2016 | 26153 | 0.030 |
Why?
| | Education, Medical, Undergraduate | 1 | 2017 | 207 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2028 | 0.030 |
Why?
| | Marijuana Smoking | 1 | 2017 | 249 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2014 | 189 | 0.020 |
Why?
| | Family Planning Services | 1 | 2014 | 93 | 0.020 |
Why?
| | Drug Compounding | 1 | 2014 | 107 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1508 | 0.020 |
Why?
| | Quality Improvement | 1 | 2021 | 1295 | 0.020 |
Why?
| | Comprehension | 1 | 2014 | 186 | 0.020 |
Why?
| | Rural Population | 1 | 2017 | 659 | 0.020 |
Why?
| | Educational Status | 1 | 2014 | 466 | 0.020 |
Why?
| | Women's Health | 1 | 2014 | 314 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2018 | 1193 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 2014 | 777 | 0.020 |
Why?
| | Communication | 1 | 2014 | 975 | 0.020 |
Why?
| | Prospective Studies | 1 | 2019 | 8057 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2014 | 1419 | 0.010 |
Why?
|
|
Borgelt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|